Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

• Phase: Phase 4

Details

• Lead Sponsor: Innovative Medical
• Treatments: Bimatoprost; Latanoprost

Criteria

Inclusion Criteria:

• · Male or female > 18 years of age

• Documented low-responder to latanoprost therapy as delineated in the outline above.

• Diagnosis of open-angle glaucoma or ocular hypertension

• Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

• · Known contraindication to bimatoprost or any component of any study medication

• Uncontrolled systemic disease

• Active ocular disease other than glaucoma or ocular hypertension

• Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)

• History of intraocular surgery within the last 3 months